A novel chimeric coronavirus spike vaccine combining SARS-CoV-2 RBD and scaffold domains from HKU-1 elicits potent neutralising antibody responses

Abstract The SARS-CoV-2 spike receptor binding domain (RBD) is the major target for neutralising antibodies. However, subdomains like RBD may constrain the availability of CD4 T follicular helper (TFH) cells and impact immunogenicity. We engineered a chimeric trimeric RBD (CTR) glycoprotein, replaci...

Descripció completa

Dades bibliogràfiques

Autors principals:	Veronica P. Zoest, Wen Shi Lee, Lydia Murdiyarso, Lauren Burmas, Phillip Pymm, Robyn Esterbauer, Andrew Kelly, Hannah G. Kelly, Isaac Barber-Axthelm, James P. Cooney, Kathryn C. Davidson, Merle Dayton, Courtney E. McAleese, Marianne Gillard, Karen Hughes, Martina L. Jones, Marc Pellegrini, Wai-Hong Tham, Ben Hughes, Stephen J. Kent, Adam K. Wheatley, Jennifer A. Juno, Hyon-Xhi Tan
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-11-01
Col·lecció:	npj Vaccines
Accés en línia:	https://doi.org/10.1038/s41541-025-01323-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!